Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b randomized double-blind placebo-controlled dose-finding study of VIT-2763 in adults with transfusion-dependent beta thalassemia
MOH_2021-11-02_010351Phase 2Not yet recruiting
- Sponsor
- CSL Vifor
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vamifeport in beta thalassemia (4 arms), sponsored by CSL Vifor. Primary endpoint: Primary endpoint not reported. Planned start Oct 2021; status: not yet recruiting.
02
Drugs
vamifeport
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on MOH_2021-11-02_010351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-11-02_010351.